Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 11-12, 2014, Pages 1324-1332

  Baert, F ^a   Vande Casteele, N ^b   Tops, S ^b   Noman, M ^a   Van Assche, G ^a   Rutgeerts, P ^a   Gils, A ^b   Vermeire, S ^a   Ferrante, M ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALBUMIN; ANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; INFLIXIMAB; MERCAPTOPURINE; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ACNE; ADULT; ALBUMIN BLOOD LEVEL; ANTIBODY DETECTION; ARTHRALGIA; ARTICLE; BODY MASS; BODY WEIGHT; COHORT ANALYSIS; COLON RESECTION; COLONOSCOPY; CONJUNCTIVITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPLASIA; ECZEMA; FEMALE; FEVER; FURUNCULOSIS; HAIR LOSS; HEADACHE; HERPES SIMPLEX; HUMAN; INDEPENDENT VARIABLE; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; PITYRIASIS; PITYRIASIS ROSEA; PSORIASIS; PUSTULOSIS PALMOPLANTARIS; RECEIVER OPERATING CHARACTERISTIC; REMISSION; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; TOOTH ABSCESS; ULCERATIVE COLITIS; BLOOD; COLITIS, ULCERATIVE; MIDDLE AGED; TIME; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84909647171     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12968     Document Type: Article

References (26)

1. Danese S. Adalimumab in ulcerative colitis: ready for prime time. Dig Liver Dis 2013; 45: 8-13.
2. Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of antitumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther 2014; 39: 660-71.
3. Mehta SJ, Silver AR, Lindsay JO. Review article: strategies for the management of chronic unremitting ulcerative colitis. Aliment Pharmacol Ther 2013; 38: 77-97.
4. Danese S, Colombel JF, Peyrin-Biroulet L, Rutgeerts P, Reinisch W. Review article: the role of anti-TNF in the management of ulcerative colitis - past, present and future. Aliment Pharmacol Ther 2013; 37: 855-66.
5. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-7.
6. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-65 e1-3.
7. Armuzzi A, Biancone L, Daperno M, et al. Adalimumab in active ulcerative colitis: a "real-life" observational study. Dig Liver Dis 2013; 45: 738-43.
8. Travis S. Does it all ADA up? Adalimumab for ulcerative colitis Gut 2011; 60: 741-2.
9. Vande Casteele N, Feagan BG, Gils A, et al. Therapeutic drug monitoring in in flammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep 2014; 16: 378.
10. Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis 2013; 7: 736-43.
11. Cornillie F, Hanauer S, Diamond R, et al. Early serum infliximab trough level, clinical disease activity and CRP as markers of sustained benefit of infliximab treatment in Crohn's disease: a post-hoc analysis of the ACCENT1 trial. Am J Gastroenterol 2011; 106: S462-3.
12. Ferrante M, Arias MT, Vermeire S, et al. Long-term outcome of infliximab therapy in patients with ulcerative colitis: identification of predictors of relapse-free and colectomy-free survival. Gastroenterology 2013; 144: S-426.
13. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137: 1628-40.
14. Vande Casteele N, Ballet V, Van Assche G, Rutgeerts P, Vermeire S, Gils A. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment. Gut 2012; 61: 321.
15. Vande Casteele N, Buurman DJ, Sturkenboom MGG, et al. Detection of infl iximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012; 36: 765-71.
16. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infl iximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 1133-9.
17. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011; 106: 685-98.
18. de Silva PS, Nguyen DD, Sauk J, Korzenik J, Yajnik V, Ananthakrishnan AN. Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in infl ammatory bowel disease. Aliment Pharmacol Ther 2012; 36: 459-66.
19. Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with infl ammatory bowel diseases. Clin Gastroenterol Hepatol 2014; 12: 80-4.
20. Sjöberg M, Magnuson A, Björk J, et al. Infliximab as rescue therapy in hospitalised patients with steroidrefractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. Aliment Pharmacol Ther 2013; 38: 377-87.
21. Croft A, Walsh A, Doecke J, Cooley R, Howlett M, Radford-Smith G. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Aliment Pharmacol Ther 2013; 38: 294-302.
22. Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 2009; 65: 1211-28.
23. Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 2010; 48: 297-308.
24. Rubin DT, Mody R, Davis KL, Wang CC. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn 's disease. Aliment Pharmacol Ther 2014; 39: 1143-55.
25. Brandste J, Wildenberg M, de Bruyn J, et al. Fecal loss in infliximab as a cause of lack of response in severe infl ammatory bowel disease. Gastroenterology 2013; 144: S-36.
26. Laharie D, Filippi J, Roblin X, et al. Impact of mucosal healing on longterm outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment Pharmacol Ther 2013; 37: 998-1004.